We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Angiotech Pharmaceuticals - Common Shares (MM) | NASDAQ:ANPI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2113 | 0 | 01:00:00 |
From May 2019 to May 2024
VANCOUVER, Jan. 13 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. (OTCQB: ANPI, TSX: ANP) ("Angiotech" or the "Company") today announced that trading of shares of the Company's common stock will be transferred from the Nasdaq Stock Market ("Nasdaq") to the OTCQB™ Marketplace effective January 13, 2011. As previously disclosed on January 5, 2011, Angiotech received a notice from Nasdaq stating Angiotech has not regained compliance with Nasdaq's Listing Rule 5450(a)(1) within the 180 calendar day grace period ending January 3, 2011. Nasdaq's notice indicated Angiotech's common shares will be delisted on January 13, 2011.
The Company has been advised by Pink OTC Markets, Inc., which operates an electronic quotation service for securities traded over-the-counter ("OTC"), that its securities are immediately eligible for quotation on the OTCQB. The OTCQB is a market tier for OTC-traded companies that are registered and reporting with the Securities and Exchange Commission. The Company has also been advised that its shares will trade under the symbol ANPI. Investors will be able to view real-time stock quotes for ANPI at www.otcmarkets.com.
Angiotech's common shares will still be tradable on the Toronto Stock Exchange under the trading symbol "ANP".
Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will," "estimates," "continues,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable Canadian
securities laws. All such statements are made pursuant to the "safe
harbor" provisions of applicable securities legislation. Forwardlooking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2010 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forwardlooking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada and the other regions in which we operate; market
demand; technological changes that could impact our existing products
or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health
regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to conduct research and
development, to expand manufacturing and commercialization activities;
and any other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
press release to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; our failure to obtain patent protection for
discoveries; loss of patent protection resulting from thirdparty
challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain
rights to technology from licensors; liability for patent claims and
other claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to maintain,
corporate alliances relating to the development and commercialization
of our technology and products; market acceptance of our technology and
products; our ability to successfully manufacture, market and sell our
products; the availability of capital to finance our activities; our
ability to restructure and to service our debt obligations; and any
other factors referenced in our other filings with the applicable
Canadian securities regulatory authorities or the Securities and
Exchange Commission ("SEC"). For a more thorough discussion of the
risks associated with our business, see the "Risk Factors" section in
our annual report for the year ended December 31, 2009 filed with the
SEC on Form 10-K, as amended, and our quarterly report for the 3rd
quarter of 2010 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
©2011 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company. Angiotech discovers, develops and markets
innovative treatment solutions for diseases or complications associated
with medical device implants, surgical interventions and acute injury.
To find out more about Angiotech (OTCQB: ANPI, TSX: ANP), please visit
our website at www.angiotech.com.
About Pink OTC Markets Inc.
Pink OTC Markets Inc. is a financial information and technology services
company that operates an inter-dealer electronic quotation and trading
system in the Over-the-Counter, or OTC, securities market. It is not
registered with the Securities and Exchange Commission as a stock
exchange or a broker-dealer firm. Investors should contact a
broker-dealer firm to trade in a security quoted on the OTCQB or the
other OTC tiers operated by Pink OTC Markets Inc. More information is
available at www.otcmarkets.com.
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright . 13 PR Newswire
1 Year Angiotech Pharmaceuticals - Common Shares (MM) Chart |
1 Month Angiotech Pharmaceuticals - Common Shares (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions